

Cell and Gene Therapy Manufacturing Quality Control (QC) Market (Component: Equipment & Accessories, Consumables, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Market Report | 2023-08-23 | 202 pages | Transparency Market Research

AVAILABLE LICENSES:

- Single User License \$5795.00
- Multi User License \$8795.00
- Global Site License \$11795.00

Report description:

Cell and Gene Therapy Manufacturing Quality Control (QC) Market - Scope of Report

TMR's report on the global cell and gene therapy manufacturing quality control (QC) market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cell and gene therapy manufacturing quality control (QC) market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cell and gene therapy manufacturing quality control (QC) market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the cell and gene therapy manufacturing quality control (QC) market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cell and gene therapy manufacturing quality control (QC) market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cell and gene therapy manufacturing quality control (QC) market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cell and gene therapy manufacturing quality control (QC) market.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The report delves into the competitive landscape of the global cell and gene therapy manufacturing quality control (QC) market. Key players operating in the global cell and gene therapy manufacturing quality control (QC) market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cell and gene therapy manufacturing quality control (QC) market profiled in this report.

Key Questions Answered in Global Cell and Gene Therapy Manufacturing Quality Control (QC) Market Report

- What is the sales/revenue generated by cell and gene therapy manufacturing quality control (QC) across all regions during the forecast period?
- What are the opportunities in the global cell and gene therapy manufacturing quality control (QC) market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2031?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?

Cell and Gene Therapy Manufacturing Quality Control (QC) Market - Research Objectives and Research Approach

The comprehensive report on the global cell and gene therapy manufacturing quality control (QC) market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global cell and gene therapy manufacturing quality control (QC) market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cell and gene therapy manufacturing quality control (QC) market.

Table of Contents:

1. Preface
 - 1.1. Market Definition and Scope
 - 1.2. Market Segmentation
 - 1.3. Key Research Objectives
 - 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cell and Gene Therapy Manufacturing Quality Control (QC) Market
4. Market Overview
 - 4.1. Introduction
 - 4.1.1. Segment Definition
 - 4.2. Overview
 - 4.3. Market Dynamics
 - 4.3.1. Drivers
 - 4.3.2. Restraints

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.3.3. Opportunities
- 4.4. Global Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast, 2017-2031
 - 4.4.1. Market Revenue Projections (US\$ Mn)
- 5. Key Insights
 - 5.1. Technological Advancements
 - 5.2. Key Industry Events
 - 5.3. Regulatory Scenario by Region/Globally
 - 5.4. Major Research Institutes Involved
 - 5.5. COVID-19 Pandemic Impact on Industry
- 6. Global Cell and Gene Therapy Manufacturing QC Analysis and Forecast, by Component
 - 6.1. Introduction & Definition
 - 6.2. Key Findings/Developments
 - 6.3. Market Value Forecast, by Component, 2017-2031
 - 6.3.1. Equipment & Accessories
 - 6.3.2. Consumables
 - 6.3.3. Others
 - 6.4. Market Attractiveness Analysis, by Component
- 7. Global Cell and Gene Therapy Manufacturing QC Analysis and Forecast, by Analytical Method
 - 7.1. Introduction & Definition
 - 7.2. Key Findings/Developments
 - 7.3. Market Value Forecast, by Analytical Method, 2017-2031
 - 7.3.1. Sterility Testing
 - 7.3.2. Purity Testing
 - 7.3.3. Potency Testing
 - 7.3.4. Identity Testing
 - 7.3.5. Others
 - 7.4. Market Attractiveness Analysis, by Analytical Method
- 8. Global Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast, by Process
 - 8.1. Introduction & Definition
 - 8.2. Key Findings/Developments
 - 8.3. Market Value Forecast, by Process, 2017-2031
 - 8.3.1. Upstream Processes
 - 8.3.2. Downstream Processes
 - 8.3.3. Process Development
 - 8.4. Market Attractiveness Analysis, by Process
- 9. Global Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast, by End-user
 - 9.1. Introduction & Definition
 - 9.2. Key Findings/Developments
 - 9.3. Market Value Forecast, by End-user, 2017-2031
 - 9.3.1. Pharmaceutical & Biotechnology Companies
 - 9.3.2. Contract Manufacturing Organizations (CMOs)
 - 9.4. Market Attractiveness Analysis, by End-user
- 10. Global Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast, by Region
 - 10.1. Key Findings
 - 10.2. Market Value Forecast, by Region, 2017-2031
 - 10.2.1. North America
 - 10.2.2. Europe

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.2.3. Asia Pacific
- 10.2.4. Latin America
- 10.2.5. Middle East & Africa
- 10.3. Market Attractiveness Analysis, by Region
- 11. North America Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast
 - 11.1. Introduction
 - 11.1.1. Key Findings
 - 11.2. Market Value Forecast, by Component, 2017-2031
 - 11.2.1. Equipment & Accessories
 - 11.2.2. Consumables
 - 11.2.3. Others
 - 11.3. Market Value Forecast, by Analytical Method, 2017-2031
 - 11.3.1. Sterility Testing
 - 11.3.2. Purity Testing
 - 11.3.3. Potency Testing
 - 11.3.4. Identity Testing
 - 11.3.5. Others
 - 11.4. Market Value Forecast, by Process, 2017-2031
 - 11.4.1. Upstream Processes
 - 11.4.2. Downstream Processes
 - 11.4.3. Process Development
 - 11.5. Market Value Forecast, by End-user, 2017-2031
 - 11.5.1. Pharmaceutical & Biotechnology Companies
 - 11.5.2. Contract Manufacturing Organizations (CMOs)
 - 11.6. Market Value Forecast, by Country, 2017-2031
 - 11.6.1. U.S.
 - 11.6.2. Canada
 - 11.7. Market Attractiveness Analysis
 - 11.7.1. By Component
 - 11.7.2. By Analytical Method
 - 11.7.3. By Process
 - 11.7.4. By End-user
 - 11.7.5. By Country
- 12. Europe Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast
 - 12.1. Introduction
 - 12.1.1. Key Findings
 - 12.2. Market Value Forecast, by Component, 2017-2031
 - 12.2.1. Equipment & Accessories
 - 12.2.2. Consumables
 - 12.2.3. Others
 - 12.3. Market Value Forecast, by Analytical Method, 2017-2031
 - 12.3.1. Sterility Testing
 - 12.3.2. Purity Testing
 - 12.3.3. Potency Testing
 - 12.3.4. Identity Testing
 - 12.3.5. Others
 - 12.4. Market Value Forecast, by Process, 2017-2031

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.4.1. Upstream Processes
- 12.4.2. Downstream Processes
- 12.4.3. Process Development
- 12.5. Market Value Forecast, by End-user, 2017-2031
 - 12.5.1. Pharmaceutical & Biotechnology Companies
 - 12.5.2. Contract Manufacturing Organizations (CMOs)
- 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
 - 12.6.1. Germany
 - 12.6.2. U.K.
 - 12.6.3. France
 - 12.6.4. Italy
 - 12.6.5. Spain
 - 12.6.6. Rest of Europe
- 12.7. Market Attractiveness Analysis
 - 12.7.1. By Component
 - 12.7.2. By Analytical Method
 - 12.7.3. By Process
 - 12.7.4. By End-user
 - 12.7.5. By Country/Sub-region
- 13. Asia Pacific Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast
 - 13.1. Introduction
 - 13.1.1. Key Findings
 - 13.2. Market Value Forecast, by Component, 2017-2031
 - 13.2.1. Equipment & Accessories
 - 13.2.2. Consumables
 - 13.2.3. Others
 - 13.3. Market Value Forecast, by Analytical Method, 2017-2031
 - 13.3.1. Sterility Testing
 - 13.3.2. Purity Testing
 - 13.3.3. Potency Testing
 - 13.3.4. Identity Testing
 - 13.3.5. Others
 - 13.4. Market Value Forecast, by Process, 2017-2031
 - 13.4.1. Upstream Processes
 - 13.4.2. Downstream Processes
 - 13.4.3. Process Development
 - 13.5. Market Value Forecast, by End-user, 2017-2031
 - 13.5.1. Pharmaceutical & Biotechnology Companies
 - 13.5.2. Contract Manufacturing Organizations (CMOs)
 - 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
 - 13.6.1. China
 - 13.6.2. Japan
 - 13.6.3. India
 - 13.6.4. Australia & New Zealand
 - 13.6.5. Rest of Asia Pacific
 - 13.7. Market Attractiveness Analysis
 - 13.7.1. By Component

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.7.2. By Analytical Method
- 13.7.3. By Process
- 13.7.4. By End-user
- 13.7.5. By Country/Sub-region
- 14. Latin America Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast
 - 14.1. Introduction
 - 14.1.1. Key Findings
 - 14.2. Market Value Forecast, by Component, 2017-2031
 - 14.2.1. Equipment & Accessories
 - 14.2.2. Consumables
 - 14.2.3. Others
 - 14.3. Market Value Forecast, by Analytical Method, 2017-2031
 - 14.3.1. Sterility Testing
 - 14.3.2. Purity Testing
 - 14.3.3. Potency Testing
 - 14.3.4. Identity Testing
 - 14.3.5. Others
 - 14.4. Market Value Forecast, by Process, 2017-2031
 - 14.4.1. Upstream Processes
 - 14.4.2. Downstream Processes
 - 14.4.3. Process Development
 - 14.5. Market Value Forecast, by End-user, 2017-2031
 - 14.5.1. Pharmaceutical & Biotechnology Companies
 - 14.5.2. Contract Manufacturing Organizations (CMOs)
 - 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
 - 14.6.1. Brazil
 - 14.6.2. Mexico
 - 14.6.3. Rest of Latin America
 - 14.7. Market Attractiveness Analysis
 - 14.7.1. By Component
 - 14.7.2. By Analytical Method
 - 14.7.3. By Process
 - 14.7.4. By End-user
 - 14.7.5. By Country/Sub-region
- 15. Middle East & Africa Cell and Gene Therapy Manufacturing QC Market Analysis and Forecast
 - 15.1. Introduction
 - 15.1.1. Key Findings
 - 15.2. Market Value Forecast, by Component, 2017-2031
 - 15.2.1. Equipment & Accessories
 - 15.2.2. Consumables
 - 15.2.3. Others
 - 15.3. Market Value Forecast, by Analytical Method, 2017-2031
 - 15.3.1. Sterility Testing
 - 15.3.2. Purity Testing
 - 15.3.3. Potency Testing
 - 15.3.4. Identity Testing
 - 15.3.5. Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.4. Market Value Forecast, by Process , 2017-2031
 - 15.4.1. Upstream Processes
 - 15.4.2. Downstream Processes
 - 15.4.3. Process Development
- 15.5. Market Value Forecast, by End-user, 2017-2031
 - 15.5.1. Pharmaceutical & Biotechnology Companies
 - 15.5.2. Contract Manufacturing Organizations (CMOs)
- 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
 - 15.6.1. GCC Countries
 - 15.6.2. South Africa
 - 15.6.3. Rest of Middle East & Africa
- 15.7. Market Attractiveness Analysis
 - 15.7.1. By Component
 - 15.7.2. By Analytical Method
 - 15.7.3. By Process
 - 15.7.4. By End-user
 - 15.7.5. By Country/Sub-region
- 16. Competition Landscape
 - 16.1. Market Player - Competition Matrix (by tier and size of companies)
 - 16.2. Market Share Analysis, by Company, 2022
 - 16.3. Company Profiles
 - 16.3.1. bioMerieux SA
 - 16.3.1.1. Company Overview
 - 16.3.1.2. Financial Overview
 - 16.3.1.3. Product Portfolio
 - 16.3.1.4. Business Strategies
 - 16.3.1.5. Recent Developments
 - 16.3.2. Bio-Rad Laboratories, Inc.
 - 16.3.2.1. Company Overview
 - 16.3.2.2. Financial Overview
 - 16.3.2.3. Product Portfolio
 - 16.3.2.4. Business Strategies
 - 16.3.2.5. Recent Developments
 - 16.3.3. Bio-Techne Corporation
 - 16.3.3.1. Company Overview
 - 16.3.3.2. Financial Overview
 - 16.3.3.3. Product Portfolio
 - 16.3.3.4. Business Strategies
 - 16.3.3.5. Recent Developments
 - 16.3.4. QIAGEN
 - 16.3.4.1. Company Overview
 - 16.3.4.2. Financial Overview
 - 16.3.4.3. Product Portfolio
 - 16.3.4.4. Business Strategies
 - 16.3.4.5. Recent Developments
 - 16.3.5. Charles River Laboratories International, Inc.
 - 16.3.5.1. Company Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.3.5.2. Financial Overview
- 16.3.5.3. Product Portfolio
- 16.3.5.4. Business Strategies
- 16.3.5.5. Recent Developments
- 16.3.6. Lonza Group AG
 - 16.3.6.1. Company Overview
 - 16.3.6.2. Financial Overview
 - 16.3.6.3. Product Portfolio
 - 16.3.6.4. Business Strategies
 - 16.3.6.5. Recent Developments
- 16.3.7. Merck KGaA
 - 16.3.7.1. Company Overview
 - 16.3.7.2. Financial Overview
 - 16.3.7.3. Product Portfolio
 - 16.3.7.4. Business Strategies
 - 16.3.7.5. Recent Developments
- 16.3.8. Intertek Group plc
 - 16.3.8.1. Company Overview
 - 16.3.8.2. Financial Overview
 - 16.3.8.3. Product Portfolio
 - 16.3.8.4. Business Strategies
 - 16.3.8.5. Recent Developments
- 16.3.9. Thermo Fisher Scientific Inc.
 - 16.3.9.1. Company Overview
 - 16.3.9.2. Financial Overview
 - 16.3.9.3. Product Portfolio
 - 16.3.9.4. Business Strategies
 - 16.3.9.5. Recent Developments
- 16.3.10. Eurofins Scientific S.E.
 - 16.3.10.1. Company Overview
 - 16.3.10.2. Financial Overview
 - 16.3.10.3. Product Portfolio
 - 16.3.10.4. Business Strategies
 - 16.3.10.5. Recent Developments
- 16.3.11. F. Hoffmann-La Roche Ltd.
 - 16.3.11.1. Company Overview
 - 16.3.11.2. Financial Overview
 - 16.3.11.3. Product Portfolio
 - 16.3.11.4. Business Strategies
 - 16.3.11.5. Recent Developments

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Cell and Gene Therapy Manufacturing Quality Control (QC) Market (Component: Equipment & Accessories, Consumables, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Market Report | 2023-08-23 | 202 pages | Transparency Market Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5795.00
	Multi User License	\$8795.00
	Global Site License	\$11795.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-04"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Signature

An empty rectangular box with a thin black border, intended for a signature.